New combo aims to keep prostate cancer in check with lower chemo dose
Disease control
Not yet recruiting
This study tests a combination of darolutamide, hormone therapy, and a lower dose of the chemotherapy drug docetaxel in men with metastatic hormone-sensitive prostate cancer. The goal is to see if this approach can keep PSA levels very low (below 0.2 ng/mL) at 24 weeks while redu…
Phase: PHASE2 • Sponsor: Yonghong Li • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC